Every 8-K that Catheter Precision, Inc. (VTAK) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow VTAK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VTAK filings page.
Catheter Precision, Inc. (VTAK) will change its name to Flyte Aviation, Inc. and effect a 1-for-10 reverse stock split at 12:01 a.m. Eastern Time on October 5, 2026. The company said issued and outstanding common shares will decrease from approximately 21,019,874 to approximately 2,101,987; authorized capital stock will remain 500 million common shares and 10 million preferred shares. Trading under the new name and VJET symbol is expected to begin at the October 5 opening.
Stockholders approved a 5,000,000-share increase to the 2023 Equity Incentive Plan reserve and a one-time repricing of options with exercise prices above fair market value to $0.152 per share. After the reverse split, the exercise price of each repriced option will be $1.52 per share; the repricing does not change option share counts, expiration dates or vesting schedules.
Catheter Precision, Inc. approved an amendment to change its name to Flyte Aviation, Inc. and effect a 1-for-10 reverse stock split, expected to become effective at 12:01 a.m. Eastern Time on October 5, 2026. Stockholders approved the split at a special meeting on April 15, 2026, and the Board selected the ratio within the approved range; the name change did not require stockholder approval.
The company intends to file a certificate of amendment. At the effective time, every ten shares issued and outstanding or held in treasury will be combined into one share. No fractional shares will be issued; holders otherwise entitled to a fraction will receive their pro rata portion of net proceeds from the exchange agent’s aggregation and sale of those shares. The split will not change the common stock’s par value or authorized share count, and outstanding equity awards, warrants, and convertible securities will be adjusted proportionately under their terms. Split-adjusted trading is expected to begin on the NYSE American under the name Flyte Aviation, Inc. and ticker VJET at the opening of trading on October 5, 2026.
Catheter Precision, Inc. completed a private financing on July 30, 2026, issuing 2,821 shares of Series C-4 Convertible Preferred Stock, par value $0.0001 and stated value $1,000 per share, for aggregate gross proceeds of $2,821,000.00. The securities were issued to investors exercising an Additional Investment Right under a March 9, 2026 Securities Purchase Agreement.
The Series C-4 terms are set out in a Certificate of Designation filed July 27, 2026 in Delaware. Dawson James Securities, Inc. acted as placement agent and received customary fees and expenses. The company plans to use net proceeds for working capital, general corporate purposes and to redeem all outstanding Series B Convertible Preferred Stock. The Series C-4 Preferred Stock ranks senior to common stock for dividends and liquidation rights, and any conversion into common stock will dilute existing common shareholders. The issuance relied on exemptions under Section 4(a)(2) and Rule 506(b) of Regulation D, with sales only to accredited investors and subject to transfer restrictions.
Catheter Precision, Inc. filed an amended report to add full-year 2024–2025 financial statements for Fly Flyte, Inc. and Ponderosa Air LLC (together “FLYTE”), which it acquired from Creatd, Inc. on March 9, 2026, plus unaudited pro forma results reflecting this acquisition.
FLYTE operates a private aviation platform. In 2025 it generated $986 thousand of service revenue but recorded a net loss of $4.8 million, negative operating cash flow of $2.3 million, and an accumulated deficit of $17.2 million. Year-end cash was $26 thousand with a working capital deficit of $4.4 million and stockholders’ deficit of $4.7 million.
Auditors raised substantial doubt about FLYTE’s ability to continue as a going concern due to recurring losses, negative cash flows, a leveraged balance sheet, and litigation and lease settlements, despite debt restructurings, gains on extinguishment of debt and leases, and capital contributions from prior owners. After the acquisition, Catheter Precision committed to provide financial support and is pursuing additional financing to fund ongoing operations.
Catheter Precision, Inc. completed the closing of a private placement of 3,470 shares of newly designated Series C-3 Convertible Preferred Stock, each with a $1,000 stated value, for aggregate gross proceeds of $3,470,000. The transaction followed prior stockholder approval and effectiveness of a Form S-1 registering resale of common shares issuable upon conversion.
The Series C-3 Preferred Stock is convertible at the holder’s option into common stock at an initial conversion price of $0.632 per share, subject to a $0.35 floor price the company may waive and customary anti-dilution adjustments. Conversion is limited by a 4.99% beneficial ownership cap, which holders may increase to 9.99% with 61 days’ notice. The preferred shares rank senior to common stock for dividends and liquidation, and conversion will dilute existing common holders. A Certificate of Designation filed on July 14, 2026 formally designated the 3,470 Series C-3 shares. Net proceeds are intended for working capital, loan repayment and general corporate purposes, with the offering relying on Section 4(a)(2) and Rule 506(b) exemptions.
Catheter Precision, Inc. entered a Securities Purchase Agreement to buy 2,941,176 shares of Volato Group, Inc. common stock in a private placement at $0.34 per share, for a total Subscription Amount of $1,000,000. As of June 5, 2026, the market value of these Volato securities was approximately $1,000,000.
As consideration for participating, Catheter Precision will receive certain freely tradeable equity securities of a third-party entity from Volato, which had an aggregate market value of about $1,100,000 as of June 5, 2026. Closing is subject to customary conditions, including accuracy of representations, covenant performance, and no Material Adverse Effect for Volato.
Under a related Registration Rights Agreement, Volato must file a registration statement on Form S-3 (or other appropriate form) to cover resale of the shares within 10 calendar days and use best efforts to have it declared effective under specified timing. The agreements include customary covenants, indemnities, and registration procedures.
Catheter Precision, Inc. reported first quarter 2026 results showing rapid growth and a broader business mix. Revenue for Q1 2026 rose 200% year-over-year to $432,000, up from $143,000 in Q1 2025, helped by both its core medical device business and the new Flyte aviation platform.
The medical device segment increased revenue by approximately 73%, expanded use of its VIVO and LockeT products into more hospitals, and is now present in 15 countries, backed by new clinical publications and conference presentations. The Company also completed the acquisition of Flyte, which scaled its fleet from one to three aircraft and reached a roughly $200,000 monthly revenue run rate within 22 days of post-acquisition operations.
Net loss improved markedly, narrowing to $1.7 million from $4.0 million in Q1 2025, including about $560,000 of non-cash expenses. Management highlights a dual-engine growth strategy that combines high-margin electrophysiology devices with a technology-enabled regional air mobility platform.
Catheter Precision, Inc. completed a private financing and issued new preferred stock that can convert into common shares, which may dilute existing holders over time. The company sold 3,470 shares of Series C-2 Convertible Preferred Stock at a stated value of $1,000 per share for aggregate gross proceeds of $3,470,000, primarily to fund working capital and general corporate purposes.
It also issued 11,028 shares of Series D Convertible Preferred Stock as part of the consideration for acquiring Fly Flyte, Inc. Both preferred series are initially convertible at set prices, with a floor price of $0.35 per share and anti-dilution adjustments, and include a beneficial ownership cap initially set at 4.99% that holders may increase to 9.99% with advance notice. Certificates of Designation filed in Delaware establish that these preferred shares rank senior to common stock in dividends and liquidation, reinforcing their priority but increasing potential dilution if converted.
Catheter Precision, Inc. reported the results of a Special Meeting of stockholders held on April 15, 2026. Of the 2,357,127 shares of common stock outstanding as of March 9, 2026, 1,165,698 shares were represented in person or by proxy, representing approximately 49.5% of shares entitled to vote.
Stockholders considered six proposals described in the company’s definitive proxy statement filed on March 23, 2026. The company disclosed detailed vote tallies for each proposal, including votes for, votes against, abstentions, and broker non-votes.
Catheter Precision, Inc. reported 2025 results showing revenue growth of 95% year over year but a GAAP net loss of $17.7M. After adding back non-cash items such as intangible asset impairment and debt extinguishment, the company reported a 2025 non-GAAP adjusted net loss of $7.8M.
For Q4 2025, GAAP net loss was $5.3M and non-GAAP adjusted net loss was $3.5M. Management highlighted progress in commercializing its VIVO and LockeT cardiac devices and, after year-end, completed the acquisition of Flyte, a regional air mobility company, creating two operating platforms in medical devices and aviation.
The company also disclosed risk factors, including that it does not have sufficient liquidity to fund operations through fiscal 2026 without additional financing or a strategic transaction, and outlined numerous operational, regulatory, and integration risks around its products and the Flyte expansion.
Catheter Precision, Inc. is raising capital through a private placement of preferred stock and using part of the funds to buy aviation-related assets. The company agreed to sell 1,853 shares of Series C-1 Convertible Preferred Stock for $1,853,000, initially convertible into up to 1,295,805 common shares at $1.43 per share, with future conversion prices tied to trading levels and subject to a floor that the company may waive. Investors also committed to buy additional Series C-2 and C-3 preferred shares for $1,853,000 each, and may later purchase up to $35,559,326 of Series C-4 Preferred Stock, all with variable conversion prices based on 80% of market measures and floor-price conditions. The company plans to use net proceeds for working capital, restructuring its legacy catheter business, settling legacy liabilities, simplifying its capital structure, and cutting operating expenses.
In a linked transaction, Catheter Precision agreed to acquire 80.02% of Fly Flyte, Inc. and all membership interests of Ponderosa Air, LLC from Creatd, Inc. for total consideration of $11,554,827, consisting of $776,827 cash at closing, a $5,000,000 zero‑coupon note due by December 15, 2026, and 5,778 shares of Series D Convertible Preferred Stock with an aggregate stated value of $5,778,000. Issuance and conversion of multiple preferred series depend on stockholder approval under NYSE American Section 713 and effectiveness of SEC resale registration statements. The company also amended its preferred stock designations to increase authorized Series C‑1 shares and granted registration rights for resale of common shares underlying the preferred stock.
Catheter Precision, Inc. entered into Series J Exchange Agreements to swap accrued royalty rights with CEO David Jenkins and FatBoy Capital, LP into 9,489.488 shares of new Series J Convertible Preferred Stock, representing royalty amounts with a net present value of $9,489,487.81 as of December 31, 2025.
The Series J Preferred Stock has a stated value of $1,000 per share and is convertible into common stock at a fixed price of $1.56 per share, matching the December 31, 2025 closing price. These preferred shares are collectively convertible into 6,083,005 common shares, or about 641 common shares per preferred share, if and only if stockholder approval is obtained under NYSE American rules.
The royalty rights and accrued royalty amounts are terminated as of December 31, 2025, removing this obligation. Separately, the company highlighted a strategic institutional financing for up to $36.5 million and the agreed termination of its at-the-market equity offering program, describing these steps as strengthening its balance sheet and aligning long-term institutional capital.
Catheter Precision, Inc. entered into a complex private placement financing involving common stock and multiple new series of convertible preferred stock to raise capital and restructure its balance sheet. The initial closing covers 392,608 common shares at $1.43 each and 1,616.33 shares of Series C-1 preferred, initially convertible into up to 1,130,301 common shares, for total gross proceeds of $2,177,759.00.
Investors also committed to additional Series C-2 and C-3 preferred purchases and obtained an option to buy up to $39,233,333 of Series C-4 preferred, all with conversion prices tied to future trading levels and subject to a floor that the company may waive. Net proceeds will be used to repay debt, fund general corporate needs, and unwind or restructure the legacy catheter business while simplifying liabilities and operating costs.
Separately, the company agreed to acquire 19.98% of Fly Flyte, Inc. from SEG Jets LLC in exchange for 5,250 shares of Series D preferred, valuing the stake at $5.25 million. A registration rights agreement requires Catheter Precision to register resales of common stock underlying the new preferred series. A letter agreement with existing Series B preferred and warrant holders lowers exercise and conversion prices to $1.78 per share, generating $400,621.04 in warrant exercise proceeds and converting Series B into common stock equal to 9.99% of outstanding shares immediately after conversion.
Catheter Precision, Inc. extended the maturities of several 8% Short Term Promissory Notes held by entities associated with its executive chair and CEO, David A. Jenkins. On December 31, 2025, the company entered into Second Amendments to these notes, moving their maturity dates from January 31, 2026 to January 31, 2028 for a $500,000 note held by Jenkins Family Charitable Institute and to January 31, 2029 for notes with principal amounts of $500,000, $150,000, $250,000 and $100,000 held by Mr. Jenkins and FatBoy Capital, L.P.
The filing highlights that Mr. Jenkins is the managing member of the general partner of FatBoy Capital and the settlor of the Jenkins Family Charitable Institute, and that he and his affiliates also hold stock options and rights to receive 11.77% royalties on net sales of the LockeT device. The amendments are treated as a material definitive agreement and a direct financial obligation for the company.
Catheter Precision, Inc. reported that it has given notice to terminate its At-Market-Offering Agreement with Ladenburg Thalmann & Co. Inc., which supported its at-the-market equity offering program. The termination is scheduled to be effective on November 24, 2025.
The program allowed the company to offer and sell shares of common stock with an aggregate offering price of up to $4.3 million. Before issuing the termination notice, Catheter Precision sold approximately $4.0 million of common stock under this program, and it will not owe any termination penalties.
Catheter Precision, Inc. (VTAK) reported that it furnished a press release announcing financial results for the three and nine months ended September 30, 2025. The company provided this update under Item 2.02 of the Exchange Act.
The press release is included as Exhibit 99.1 and, as stated, the information is being furnished and not deemed filed under Section 18. VTAK’s common stock trades on NYSE American.
Catheter Precision (VTAK) reported the results of a stockholder Special Meeting held on October 10, 2025. Of the 1,487,266 shares outstanding as of September 10, 2025 (the record date), 641,616 shares were represented in person or by proxy, constituting approximately 43.1% of shares entitled to vote.
Stockholders considered three proposals. Reported vote totals were: Proposal 1 — 497,162 for, 133,882 against, 10,571 abstentions; Proposal 2 — 610,134 for, 16,778 against, 14,703 abstentions; Proposal 3 — 514,362 for, 120,394 against, 6,860 abstentions.
Catheter Precision filed an 8-K to attach a legal opinion supporting its Form S-3 prospectus supplement and to announce that its LockeT surgical vessel closing device received regulatory approval in Great Britain. The press release highlights potential benefits of LockeT for patient comfort, faster recovery and increased clinical throughput, but also contains extensive forward-looking cautionary language. The company discloses material weaknesses in internal control, a history of losses, the need to raise additional funds to continue operations, and multiple operational and market risks including competition, reimbursement, supply-chain and regulatory challenges.
Catheter Precision, Inc. implemented a 1-for-19 reverse stock split of its common stock after stockholder authorization, effective at 12:01 a.m. ET on August 15, 2025. The company combined every 19 issued shares into one share and reduced issued and outstanding common shares from approximately 23,327,516 to approximately 1,227,764. The common stock continues to trade under the symbol VTAK on the NYSE American on a split-adjusted basis and received a new CUSIP number.
Authorized capital remains unchanged at 10 million preferred and 60 million common shares. Proportionate adjustments were made to outstanding stock options, warrants, conversion prices and shares available under incentive plans. Fractional shares will not be issued; holders entitled to fractions will receive cash pro rata from aggregated fractional-share sales, net of customary fees.
Catheter Precision, Inc. furnished a Current Report on Form 8-K to announce that it issued a press release on August 11, 2025 reporting its financial results for the three and six months ended June 30, 2025. The company states the full press release is attached as Exhibit 99.1 and is incorporated by reference into the report. The company also clarifies that the information furnished under Item 2.02, including Exhibit 99.1, is being furnished and not filed for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into future SEC filings unless expressly stated.
Catheter Precision, Inc. (VTAK) filed an 8-K detailing annual-meeting results and a forthcoming reverse stock split.
Only 5.81 M of 12.59 M eligible shares (46.1%) were voted. Six proposals passed: (1) re-election of director Martin Colombatto (2.57 M for); (2) issuance of up to 4.29 M shares on Series L warrant exercise; (3) issuance of up to 8.57 M shares on Series B preferred conversion; (4) issuance of 0.26 M shares for placement-agent warrants; (5) authorization of a reverse split between 1-for-5 and 1-for-19; (6) ratification of WithumSmith+Brown as auditor (4.96 M for).
The board has chosen the maximum ratio, implementing a 1-for-19 reverse split effective 15 Aug 2025. Shares outstanding will be reduced from ~23.3 M to ~1.2 M; fractional shares will be paid in cash. Authorized capital (60 M common, 10 M preferred) is unchanged, and ownership percentages are unaffected apart from cash-settled fractions. The action seeks to restore compliance with the NYSE American’s minimum bid requirement. VTAK will continue trading under its ticker, adopting new CUSIP 74933X 708.